Zdrowie i gospodarka · 02/07/2025
FDA Draft Guidance for Myelodysplastic Syndromes Treatment
The FDA is releasing a draft guidance to help industry sponsors develop drug and biological products for treating myelodysplastic syndromes (MDS), focusing on disease-modifying treatments and excluding supportive products like erythropoiesis-stimulating agents.